Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Income towards Parent Company (2016 - 2026)

Spyre Therapeutics' Income towards Parent Company history spans 11 years, with the latest figure at -$62.5 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 11.07% year-over-year to -$62.5 million; the TTM value through Dec 2025 reached -$155.2 million, up 25.39%, while the annual FY2025 figure was -$155.2 million, 25.39% up from the prior year.
  • Income towards Parent Company reached -$62.5 million in Q4 2025 per SYRE's latest filing, down from -$11.2 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$6.8 million in Q2 2021 to a low of -$217.1 million in Q2 2023.
  • Average Income towards Parent Company over 5 years is -$42.6 million, with a median of -$30.6 million recorded in 2022.
  • Peak YoY movement for Income towards Parent Company: plummeted 872.45% in 2023, then soared 83.8% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at -$20.4 million in 2021, then increased by 7.94% to -$18.8 million in 2022, then crashed by 235.67% to -$63.2 million in 2023, then grew by 10.9% to -$56.3 million in 2024, then dropped by 11.07% to -$62.5 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Income towards Parent Company are -$62.5 million (Q4 2025), -$11.2 million (Q3 2025), and -$36.7 million (Q2 2025).